{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001740279","name":"IN8BIO, INC.","summary":"IN8bio is a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases. Its DeltEx platform supports allogeneic, autologous, iPSC, and genetically modified cell therapy approaches. Key clinical programs include INB-100 for high-risk leukemia, INB-200/INB-400 for glioblastoma, and INB-600/INB-619 TCE platform targeting solid tumors, hematologic cancers, and B cell-driven autoimmune diseases such as SLE.","people":[],"products":[{"name":"INB-100","type":"platform","description":"Allogeneic DeltEx gamma-delta T cell therapy for high-risk leukemias undergoing haploidentical stem cell transplantation."},{"name":"INB-200","type":"platform","description":"DeltEx DRI autologous genetically modified gamma-delta T cell therapy for newly diagnosed glioblastoma; Phase 1 investigator-sponsored trial."},{"name":"INB-400","type":"platform","description":"Corporate-sponsored Phase 2 DeltEx DRI gamma-delta T cell therapy for newly diagnosed GBM; enrollment suspended in September 2024."},{"name":"INB-600","type":"platform","description":"Proprietary gamma-delta T cell engager (TCE) platform designed to activate and expand gamma-delta T cells for solid tumors, leukemias, lymphomas, and autoimmune diseases."},{"name":"INB-619","type":"platform","description":"CD19-targeted gamma-delta TCE candidate for B cell-driven autoimmune diseases such as SLE, demonstrating deep B cell depletion with favorable cytokine profile."},{"name":"INB-300","type":"platform","description":"Preclinical non-signaling CAR (nsCAR) gamma-delta T cell construct targeting CD33 and CD123 for solid and liquid tumors; currently paused."},{"name":"INB-500","type":"platform","description":"Preclinical iPSC-derived gamma-delta T cell program for off-the-shelf allogeneic innate cellular therapies; currently paused."},{"name":"DeltEx Platform","type":"platform","description":"Proprietary platform encompassing allogeneic, autologous, iPSC, and genetically modified gamma-delta T cell manufacturing and engineering capabilities."}],"partnerships":[{"partner_name":"Kansas University Cancer Center (KUCC)","partnership_type":"development","description":"Clinical site for INB-100 Phase 1 trial and expansion cohort in AML patients.","start_date":null},{"partner_name":"The James Comprehensive Cancer Center at The Ohio State University","partnership_type":"development","description":"Clinical site for INB-100 expansion cohort at the recommended Phase 2 dose.","start_date":null}],"affiliations":[],"origin":{"leaf":"dcffb34d76d6e138c6ccded1dac6d84d631870378746777e3041a6268cfbfdf2","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"f328697a97d8610f860f82d21f02587e3faf0c5641a9f409c0c0e8e9a44bbed5","parent":"8359b2d3d107f7cbd170b764d59d81c14cc1d6003f2c66ae2a4ab9a8a8f51ff9","source":"0001193125-26-104181","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":351,"hourly_limit":500,"remaining":149,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}